Breast Cancer Clinical Trial

Clinical Trial Finder Breast Cancer Trials

A Study Of PF-06647263 In Patients With Advanced Solid Tumors

See Locations Near You

Summary

To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

View Full Description

Full Description

The clinical study will include 2 parts. Part 1 will estimate the MTD in dose escalation cohorts in patients with advanced solid tumors for whom no standard therapy is available in order to establish the RP2D. Part 2 will include patients with previously treated metastatic triple negative breast cancer (TNBC).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available
Performance Status of 0 or 1
Adequate bone marrow, kidney, and liver function
Part 2 includes advanced triple negative breast cancer patients.

Exclusion Criteria:

Brain metastases requiring steroids
Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
Active and clinically significant bacterial, fungal or viral infection

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

60

Study ID:

NCT02078752

Recruitment Status:

Terminated

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 8 Locations for this study

See Locations Near You

Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Brigham & Women's Hospital (BWH)
Boston Massachusetts, 02115, United States
Dana-Farber Cancer Institute (DFCI)
Boston Massachusetts, 02215, United States
Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Comprehensive Cancer Centers Of Nevada
Las Vegas Nevada, 89169, United States
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States
Tennessee Oncology, PLLC
Nashville Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Huntsman Cancer Hospital / University of Utah
Salt Lake City Utah, 84112, United States
Huntsman Cancer Institute-University of Utah
Salt Lake City Utah, 84112, United States
Load More

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

60

Study ID:

NCT02078752

Recruitment Status:

Terminated

Sponsor:


Pfizer

How clear is this clinincal trial information?

Clinical Trial Resources

SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials for Breast Cancer
Have You Been Diagnosed With Late-Stage Breast Cancer? Know That You Have Treatment Options.
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider